ReviewMolecular neurobiology2016
Are microRNAs the Molecular Link Between Metabolic Syndrome and Alzheimer's Disease?
Review in Molecular neurobiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Insulin resistance: a connecting link between Alzheimer's disease and metabolic disorder.Metabolic brain disease · 2021Review
- Olfactory Dysfunction in Diabetic Rats is Associated with miR-146a Overexpression and Inflammation.Neurochemical research · 2020Article
- MicroRNA silencing: A promising therapy for Alzheimer's disease.The neuroscience chronicles · 2020Article
- Over-expression of miR-34c leads to early-life visceral fat accumulation and insulin resistance.Scientific reports · 2019Article
- Klotho at the Edge of Alzheimer's Disease and Senile Depression.Molecular neurobiology · 2019Review
- The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer's Dementia.Frontiers in aging neuroscience · 2019Article
- Review
- Chromosome 21-Encoded microRNAs (mRNAs): Impact on Down's Syndrome and Trisomy-21 Linked Disease.Cellular and molecular neurobiology · 2018Article
- A microRNA cluster (let-7c, miRNA-99a, miRNA-125b, miRNA-155 and miRNA-802) encoded at chr21q21.1-chr21q21.3 and the phenotypic diversity of Down's syndrome (DS; trisomy 21).Journal of nature and science · 2017Article
- MiR-144 promotes β-amyloid accumulation-induced cognitive impairments by targeting ADAM10 following traumatic brain injury.Oncotarget · 2017Article
- A Review of Biomarkers for Alzheimer's Disease in Down Syndrome.Neurology and therapy · 2017Review
- Impact of legumes and plant proteins consumption on cognitive performances in the elderly.Journal of translational medicine · 2017Article
- Excessive expression of miR-27 impairs Treg-mediated immunological tolerance.The Journal of clinical investigation · 2017Article
- Modulation of miR-146a/complement factor H-mediated inflammatory responses in a rat model of temporal lobe epilepsy.Bioscience reports · 2016Article
- The Potentials and Pitfalls of Microarrays in Neglected Tropical Diseases: A Focus on Human Filarial Infections.Microarrays (Basel, Switzerland) · 2016Review
- Wnt-5a-regulated miR-101b controls COX2 expression in hippocampal neurons.Biological research · 2016Article
- MicroRNA (miRNA)-Mediated Pathogenetic Signaling in Alzheimer's Disease (AD).Neurochemical research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the most common cause of dementia in people over 65 years of age. At present, treatment options for AD address only its symptoms, and there are no available treatments for the prevention or delay of the disease process. Several preclinical and epidemiological studies have linked metabolic risk factors such as hypertension, obesity, dyslipidemia, and diabetes to the pathogenesis of AD. However, the molecular mechanisms that underlie this relationship are not fully understood. Considering that less than 1% of cases of AD are attributable to genetic factors, the identification of new molecular targets linking metabolic risk factors to neuropathological processes is necessary for improving the diagnosis and treatment of AD. The dysregulation of microRNAs (miRNAs), small non-coding RNAs that regulate several biological processes, has been implicated in the development of different pathologies. In this review, we summarize some of the relevant evidence that points to the role of miRNAs in metabolic syndrome (MetS) and AD and propose that miRNAs may be a molecular link in the complex relationship between both diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.